Stocks / NASDAQ / Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc.

Our Opinion

Inhibikase Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they use animals for product testing.

“In validated preclinical animal models, IkT-148009 was able to drive functional recovery in the brain and gastrointestinal tract, clear pathologic alpha-synuclein aggregates, and block neurodegeneration and neuroinflammation. With the initiation of our Phase 1b extension study in Parkinson’s patients, we are excited that we may be closer to finally impacting this devastating disease that affects millions of people worldwide.” Read the following article

Company Description

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s product candidates include IkT-148009, IkT-001pro, and IKT-01427.

Company Website: